Two-day program October 27–28 will feature 100+ speakers and 50+ presenting companies exploring the future of biopharma, from AI and investment to policy and global innovation

NEW YORK, Sept. 29, 2026 /PRNewswire/ — Demy-Colton today announced the agenda for BioFuture™ 2026, taking place October 27–28 at Cure, 345 Park Avenue South in New York City. The conference will bring together leaders from across biopharma, healthcare, investment, technology and policy for discussions, company presentations, networking and one-to-one partnering, followed by virtual partnering November 3–5.

BioFuture allows innovators, investors and industry decision-makers to examine the scientific, technological, financial and policy developments shaping the future of biopharma. This year’s program spans AI, oncology, neuroscience, MedTech, emerging therapeutics, biotech financing, regulatory and policy issues, and global drug development, with speakers from organizations including Johnson & Johnson, Regeneron Pharmaceuticals, Schrödinger, Piper Sandler and Mizuho Securities. Sponsors for BioFuture 2026 include Regeneron Pharmaceuticals, Russo Partners, WuXi AppTec, Blue Matter, Cure, Evotec, Ipsen, Thermo Fisher Scientific, Big4Bio, HMA Consulting, Withum and Hogan Lovells Cadwalader.

Beyond the main-stage discussions, one-hour, industry analyst-led Spotlight Panels will highlight companies across biopharma, digital medicine, AI, TechBio and other emerging areas. The Seed Showcase will allow early-stage companies to present their technologies and business models and receive real-time feedback from investors and industry leaders. Networking receptions and one-to-one partnering will create additional opportunities for attendees to connect with investors, potential partners and other leaders across the life sciences ecosystem.

“Some of the most important questions facing biopharma today can’t be answered by science alone,” said Sara Jane Demy, Founder and CEO of Demy-Colton. “Breakthrough innovation also depends on capital, policy, regulation, partnerships and the ability to translate new technologies into medicines that reach patients. BioFuture brings those worlds together so leaders can challenge assumptions, exchange perspectives and build relationships that can help move innovation forward.”

Agenda highlights include:

• Health as a Right vs. Health as a Business: Can Biopharma Do Both?, featuring Paul Hastings, Nkarta; Nouhad Husseini, Regeneron Pharmaceuticals; Alanna Temme, Midsized Biotech Alliance of America; and Priscilla VanderVeer, No Patient Left Behind, moderated by Dennis Purcell, Aisling Capital.
• Funding Has Come Back: But Has It?, featuring Scott Barry, EW Healthcare Partners; Kevin Eisele, William Blair; Dennis Purcell, Aisling Capital; and Robert Masella, Goodwin, moderated by William Kridel Jr., Ferghana Partners.
• Next Wave of Innovation: Navigating Policy and Regulatory Headwinds, featuring Cartier Esham, Esham Strategies; Jennifer Hawks Bland, NewYorkBIO; William Soliman, ACMA; Blake Wilson, Hogan Lovells Cadwalader; and Susan Winckler, Reagan-Udall Foundation, moderated by Lori Ellis, Open Door Salon.
• Leading the AI-First Biopharma Revolution: Faster Decisions. Faster Medicines. Better Outcomes, featuring Maneesh Goyal, Mayo Clinic Platform; William Soliman, ACMA; and Fabio Thiers, ConverGen AI, moderated by MaryAnne Rizk, Rizk Management Advisors.
• AI & Deep Tech: Refining Health Innovation – Drug Discovery, Diagnostics and Delivery, featuring Tara Austraat-Churik, Blue Matter; Karen Akinsanya, Schrödinger; Ingrid Müller, Evotec; and Rachel Ravens, 46Health, moderated by Beth Rogozinski, Oncoustics.
   
• China: A Global Biotech Player, featuring Zairan Liu, PharmCube; Josie Zhou, McKinsey & Company; and Maria Luisa Pineda, Envisagenics, moderated by Ignacio Guerrero-Ros, Russo Partners.
• Leveraging Deep Disease Area Expertise to Bring Transformational Medicines to Patients, a closing fireside chat with John Reed, M.D., Ph.D., Johnson & Johnson, interviewed by Jeremy Abbate, Scientific American.

The full agenda is available here. Registration for BioFuture 2026 is still open. Qualified investors and media may apply for complimentary registration.

About BioFuture™

BioFuture, produced by Demy-Colton, brings together leaders from biotechnology, pharmaceuticals, healthcare, technology, investment and policy to explore the scientific, business and societal forces shaping the future of biopharma. Through discussions, company presentations, partnering and networking, BioFuture connects innovators with investors, strategic partners and industry leaders across the healthcare ecosystem.

For more information, visit www.biofuture.com.

About Demy-Colton

Demy-Colton is a leading life sciences and digital health events organization at the forefront of building networks between innovative life sciences companies and industry stakeholders. Its unique events facilitate networking on a global scale, including Biotech Showcase™, BioFuture™, Global Biotech CEO Summit™, Executive Clinics™, and Demy-Colton Virtual Salons™. These events build networking communities that transcend geographical boundaries and establish ongoing, high-value relationships among the industry’s top decision-makers, investors and thought leaders.

For more information, visit www.demy-colton.com.

Media Contacts
Rachelle Babb, Ph.D., or Ignacio Guerrero-Ros, Ph.D.
Russo Partners, LLC
rachelle.babb@russopartnersllc.com
Ignacio.guerrero-ros@russopartnersllc.com
929-325-7559
646-942-5604

Sponsorship and Presenting Company Contact:
Lila Taylor
Demy-Colton
ltaylor@demy-colton.com

View original content:https://www.prnewswire.com/news-releases/biofuture-2026-convenes-industry-leaders-in-new-york-city-to-explore-the-trends-reshaping-biopharma-and-healthcare-302892518.html

SOURCE Demy-Colton